Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Ticagrelor

Criteria

Inclusion Criteria:

• Patients must have severe kidney disease

• Subjects who are matched to the kidney disease patients in terms of weight, age, and sex must have normal kidneys

• All women must be post-menopausal (no longer menstruating) or surgically sterile

Exclusion Criteria:

• Patients requiring dialysis

• History of allergy to aspirin or clopidogrel

• Have increased bleeding risk (for instance uncontrolled high blood pressure or a recent major injury)

• Recent history of fainting or light-headedness